IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY | Zendy

Naveen Kishoria | Zendy; Shuchi Mathur | Zendy; Veeram Parmar | Zendy; Rimple Jeet Kaur | Zendy; Harish Agarwal | Zendy; Bhawani Shankar Parihar | Zendy; Somil Verma | Zendy

Open Access

IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY

Author(s) -

Naveen Kishoria,

Shuchi Mathur,

Veeram Parmar,

Rimple Jeet Kaur,

Harish Agarwal,

Bhawani Shankar Parihar,

Somil Verma

Publication year - 2020

Publication title -

paripex-indian journal of research

Language(s) - English

Resource type - Journals

ISSN - 2250-1991

DOI - 10.36106/paripex/4801859

Subject(s) - pneumonia , coronavirus , medicine , covid-19 , etiology , disease , ivermectin , atypical pneumonia , virology , outbreak , infectious disease (medical specialty) , veterinary medicine

A cluster of pneumonia cases of unknown etiology was reported from the city of Wuhan, in the Hubei province of China, in December 2019. A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of the disease which was subsequently termed as the coronavirus disease (COVID-19) by the World Health Organization (WHO). SARS-CoV-2 mainly affects the lower res-piratory tract and manifests as pneumonia in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research